Which GLP-1 Gives the Steadiest Glucose?

If your goal is the flattest, steadiest glucose line, does it matter which GLP-1 you're on? A little, though probably less than the marketing implies. Here's what the evidence ranks, and where it honestly runs out.

The class as a whole wins first

Start with the big picture. As a class, GLP-1 receptor agonists produce the largest reduction in glucose variability of any glucose-lowering group. In people with type 2 diabetes, they rank first across the board, ahead of DPP-4 inhibitors, SGLT2 inhibitors, and the older secretagogues (Oh 2022). So the most important choice, a GLP-1 versus something else for steadiness, is already settled in the GLP-1's favor. The within-class question is the smaller one.

Within the class, differences are modest

Among the GLP-1s themselves, the modern once-weekly agents look broadly similar on CGM. Head-to-head, semaglutide and dulaglutide produce comparable glucose profiles, with semaglutide showing a small edge on some excursion metrics (Kurozumi 2023). Longer-acting agents tend to give slightly steadier day-to-day profiles than shorter-acting ones. In the GRADE trial's CGM substudy, liraglutide delivered low variability and high time in range with minimal time below range (Bergenstal 2026). Real differences exist, but they're small next to the class-level effect.

Where tirzepatide fits

Tirzepatide (Mounjaro, Zepbound) adds GIP action and posts strong CGM numbers, but against insulin rather than a GLP-1 (Battelino 2022). No trial has compared it head-to-head with a GLP-1 receptor agonist on CGM metrics, so "tirzepatide gives steadier glucose than semaglutide" is an unproven claim right now, however plausible it sounds. If steadiness is your goal, that specific ranking simply doesn't have evidence behind it yet.

And how it stacks up against SGLT2 inhibitors

Since people often weigh a GLP-1 against an SGLT2 inhibitor, one point is worth noting. Both reduce variability meaningfully, with no significant between-class difference in one focused meta-analysis, though SGLT2 inhibitors tend to lower average glucose a bit more (Lee 2021). The broader ranking still puts GLP-1s first for variability specifically (Oh 2022). Both are reasonable when stability is the goal.

So which should you pick?

For steadiness, the honest guidance is that any modern GLP-1 gets you most of the way, and the differences between them are small enough that other factors usually matter more: dosing schedule, weight-loss goals, side-effect tolerance, cost, and coverage. All of this is type 2 diabetes evidence. If you're non-diabetic, treat the rankings as background and watch your own CGM response to whichever drug you're actually on.

The class choice matters more than the brand choice. GLP-1s lead all drug classes on glucose steadiness in type 2 diabetes, and within the class the modern agents run close, with semaglutide slightly ahead on some metrics. The tirzepatide-versus-GLP-1 steadiness question stays unproven. Pick on the practical factors, then let your sensor confirm what it's doing for you.